Saturday 17 October 2026 Export LYEL’s income statement to Excel — free account

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024. In the quarter to June 2026, revenue fell 50.0%, EPS grew 33.6% and free cash flow grew 1.31%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

8.12 0.07 −0.85%

Follow LYEL

Alert me

Market cap: $200.7M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 2/9
Altman Z: −5.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 25.00

Total sells 0.60

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	2	—	—	—	—	—	—	—
Sell	4	1	—	7	—	—	4	1	2	7	—	1

Insider Ownership 62.08%

Capital & Financial Ratios $m

Market Cap 200.70

Revenue 0.03

Net Income (248.48)

Free Cash Flow (174.87)

Net Debt (204.10)

Current Ratio 5.36

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.56)

P/S ratio 7,009.20

P/B ratio 0.81

Past 5Y EPS Growth —

This Y EPS Growth 54.95%

Next Y EPS Growth (4.98%)

Next Y revenue growth (66.94%)

Next 5Y EPS Growth 26.95%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 73.73%

10-year low 10-year high

P/B against its own 10 years 44.10%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	546	371	247	204
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	555	380	261	214

	2023	2024	2025	Q'26
Payables	5	5	3	4
ST’ Debt	—	—	—	—
Other	2	0	—	—
	35	54	49	40

Compound Annual Growth %

	10y	5y	3y
Sales	—	(65.85%)	(92.48%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(33.22%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	0
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	1	36	0	48	85
’21	2	3	3	3	11
’20	1	3	1	—	8

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(39)	(34)	—	—	—
’25	(55)	(34)	(29)	(32)	(150)
’24	(42)	(38)	(35)	(47)	(162)
’23	(46)	(39)	(38)	(41)	(164)
’22	(48)	(44)	(37)	(40)	(170)
’21	(34)	(34)	(25)	(33)	(126)
’20	(24)	(113)	(22)	(27)	(161)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(39)	(34)	—	—	—
’25	(55)	(35)	(28)	(74)	(192)
’24	(42)	(38)	(35)	(79)	(194)
’23	(48)	(40)	(38)	(41)	(166)
’22	(58)	(52)	(40)	(45)	(194)
’21	(53)	(58)	(37)	(43)	(192)
’20	(24)	(126)	(34)	(52)	(212)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.10)	(1.92)	—	—	—
’25	(3.60)	(2.89)	(2.13)	(7.68)	(16.06)
’24	(4.80)	(3.60)	(3.40)	(14.40)	(26.20)
’23	(5.40)	(5.20)	(4.00)	(4.00)	(18.60)
’22	(5.60)	(3.00)	(5.60)	(0.60)	(14.80)
’21	(63.74)	(29.40)	(4.00)	(3.60)	(36.80)
’20	(0.13)	(163.50)	(51.42)	—	(308.45)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	138.00	54.80	26.40	11.64	7.65	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	396.80	174.80	79.40	65.12	45.00
People
People	Employees	—	—	—	—	188	219	274	224	300	161
	Revenue/emp, $m	—	—	—	0.00	0.04	0.05	0.31	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	1	8	11	85	0	0	0
	Gross margin, %	—	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	—	(129)	(204)	(250)	(183)	(235)	(343)	(274)
	EBT margin, %	—	—	—	(19,692.09)	(2,636.31)	(2,349.47)	(216.24)	(180,486.15)	(562,285.25)	(762,355.56)
	Net income	—	0	—	(129)	(204)	(250)	(183)	(235)	(343)	(274)
	Depreciation	—	—	—	0	5	16	17	11	5	7
Per share, $
Per share, $	Revenue	—	—	—	2.42	11.70	1.57	6.85	0.01	0.00	0.00
	Earnings	—	—	—	(476.61)	(308.45)	(36.80)	(14.80)	(18.60)	(26.20)	(16.06)
	Cash flow	—	—	—	145.39	(242.68)	(18.58)	(13.72)	(13.04)	(12.42)	(8.78)
	Capex	—	—	—	(59.10)	(77.66)	(9.64)	(1.96)	(0.21)	(2.43)	(2.44)
	Free cash flow	—	—	—	86.29	(320.34)	(28.22)	(15.69)	(13.26)	(14.85)	(11.22)
	Book value	—	—	—	0.00	(441.29)	136.82	67.45	52.19	29.28	14.52
	Shares, m	—	—	—	0	1	7	12	13	13	17
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	36.98	36.98	98.78	9.80	4,073.60	2,743.40	14,614.52
	P/B	—	—	—	0.00	0.00	1.13	1.00	0.81	0.44	2.12
	EV/Sales	—	—	—	(39.71)	(39.71)	41.05	2.24	(128.12)	(3,330.82)	7,747.29
	EV/FCF	—	—	—	1.18	1.18	(2.28)	(0.98)	0.10	1.05	(1.45)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	39	(161)	(126)	(170)	(164)	(162)	(150)
	Capex	—	—	—	(16)	(51)	(66)	(24)	(3)	(32)	(42)
	Free cash flow	—	—	—	23	(212)	(192)	(194)	(166)	(194)	(192)
Balance, $m
Balance, $m	Working capital	—	—	—	418	568	580	614	520	326	212
	Total debt	—	—	—	546	1,066	68	68	—	—	—
	Net debt	—	—	—	(436)	(613)	(615)	(640)	(546)	(371)	(247)
	Shareholders’ equity	—	—	—	—	(293)	930	833	655	383	248
Returns, %
Returns, %	ROA	—	—	—	0.00	(45.81)	(24.58)	(17.74)	(27.81)	(55.28)	(66.06)
	ROIC	—	—	—	0.00	0.00	(42.62)	(60.54)	(141.99)	(1,823.39)	(17,146.38)
	ROE	—	—	—	64.61	103.12	(78.53)	(20.77)	(31.53)	(66.10)	(86.98)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LRMR Larimar Therapeutics, Inc.	$206.7M	— (loss-making)	—	—	n/m	−127.63% (below 0%: shrinking)	0.00%	0.00%	Compare
PRQR ProQR Therapeutics N.V.	$204.6M	— (loss-making)	— (loss-making)	+135.03% (above 0%: growing)	n/m	−1.06% (below 0%: shrinking)	100.00%	(100.72%)	Compare
NAGE Niagen Bioscience, Inc.	$204.2M	12.5×	15.0×	−4.28% (below 0%: shrinking)	−80.00% (below 0%: shrinking)	+140.63% (above 0%: growing)	64.84%	2.35%	Compare
LYEL Lyell Immunopharma, Inc.	$200.7M	— (loss-making)	— (loss-making)	−50.00% (below 0%: shrinking)	n/m	+1.31% (above 0%: growing)	100.00%	(1,183,425.00%)
RNAC Cartesian Therapeutics, Inc.	$199.1M	— (loss-making)	— (loss-making)	−92.91% (below 0%: shrinking)	−7.84% (below 0%: shrinking)	−6.15% (below 0%: shrinking)	100.00%	0.00%	Compare
IVVD Invivyd, Inc.	$197.1M	— (loss-making)	— (loss-making)	+21.20% (above 0%: growing)	n/m	−226.89% (below 0%: shrinking)	91.09%	(320.76%)	Compare
CGEN Compugen Ltd.	$197.0M	5.2×	— (loss-making)	+107.00% (above 0%: growing)	n/m	−155.42% (below 0%: shrinking)	(3.54%)	(339.62%)	Compare
ADCT ADC Therapeutics SA	$190.2M	— (loss-making)	— (loss-making)	+2.17% (above 0%: growing)	n/m	+50.98% (above 0%: growing)	87.80%	(132.03%)	Compare
STRO Sutro Biopharma, Inc.	$190.0M	— (loss-making)	— (loss-making)	−84.57% (below 0%: shrinking)	n/m	+14.55% (above 0%: growing)	100.00%	(303.77%)	Compare
Median of peers	$198.1M	—	—	+2.17%	—	−3.60%	89.45%	(116.37%)

All 614 Biotechnology stocks →

Lyell Immunopharma, Inc. (LYEL) key facts

Concern: Lyell Immunopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36,000.00, down 41.0% from fiscal 2024.
Concern: Lyell Immunopharma, Inc. reported a net loss of $274.4 million, or a loss of $16.06 per share, for fiscal 2025.
Lyell Immunopharma, Inc. (LYEL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LYEL traded at $8.12, a market capitalization of $200.7 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 7,009× sales.
Return on equity was −87.0% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −5.10 (distress zone) for fiscal 2025.